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tice guidelines. We also assessed association of patient characteristics with PPI prescriptions and PIPPI.
Methods: This was an observational study based on a large insurance claims database of persons aged
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to December 2017. We assessed the incidence and time trends of PPI prescriptions and PIPPI based
on doses prescribed, defining ฀11.5 g of pantoprazole dose equivalents during any consecutive 365 days
(average daily dose >31 mg) as inappropriate. Results: Among 1,726,491 eligible persons, the annual
incidence of PPI prescriptions increased from 19.7% (2012) to 23.0% (2017), ( p = <0.001), and the
incidence of PIPPI increased from 4.8% (2013) to 6.4% (2017), ( p = <0.001). Age, male gender, drugs
with bleeding risk and multimorbidity were independent determinants of PIPPI ( p = <0.001 for all).
Conclusions: This study provides evidence that one of the most prescribed drug groups is commonly
prescribed inappropriately in the general population and that this trend is increasing. Multimorbidity
and drugs with bleeding risks were strong determinants of PIPPI. Addressing PPI prescriptions exceeding
guideline recommendations could reduce polypharmacy and improve patient safety.
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Introduction
Proton-pump inhibitors (PPI) are highly effective 
antacid drugs1 and are among the most com-
monly prescribed drugs worldwide. Pantoprazole, 
one of the most popular examples, is the single 
most prescribed generic drug and generates the 
highest overall generic drug cost in Switzerland.2 
As the use of PPI has been steadily increasing, 
concerns about their inappropriate use have been 
growing. Both potential side effects3–5 and poten-
tially unnecessary expenditures6–8 are of increas-
ing interest. Many initiatives and professional 
societies advise against the prolonged use of 
PPI.9,10
From a patient- and health-economics perspec-
tive, excessive average long-term doses seem most 
relevant, as higher cumulative doses of PPI might 
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produce more side effects3 and cause more unnec-
essary costs.
Yet inappropriate use of PPI remains widespread 
and is still increasing, as multiple studies in vari-
ous settings show.11–14 Many previous estimates 
of potentially inappropriate PPI prescriptions 
(PIPPI) are highly variable, but do not define 
inappropriateness based on continuous and 
cumulative doses prescribed on the patient 
level.11,13 Accordingly, considerable uncertainty 
remains about the valid extent of PIPPI within 
the population.
Aims
We aimed to measure the population-based inci-
dence and time trends of PPI prescriptions and 
PIPPI by means of a novel method, which con-
tinuously assesses excessive cumulative doses 
based on clinical practice guidelines. We also 
assessed association of patient characteristics with 
PIPPI in comparison to PPI prescriptions.
Methods
Study design, data source and population
In this retrospective analysis, we used claims 
data of a major Swiss health insurance company 
(‘Helsana group’) covering approximately 14% 
of the Swiss population.15 All persons registered 
in Switzerland are obliged by law to contract 
basic health insurance. Individuals who cannot 
afford to pay the monthly premiums receive 
subsidies or full insurance coverage by their 
social services. Equal access to the full range of 
medical treatments including drugs is thereby 
granted to everyone, regardless of insurance 
status. Lower monthly premiums are available 
when choosing different deductible schemes. 
Deductibles range from 300 to 2500 Swiss 
Francs (CHF) yearly. In addition, optional 
alternative health plans (managed care, tele-
medicine gatekeeping and others) enable lower 
monthly premiums.
Our sample includes persons aged 18 or older 
whose records were available for at least 12 months 
from 1 January 2012 through 31 December 2017. 
Prescriptions of implausibly high cumulative 
doses were excluded.
Objectives
We defined our main objectives as follows:
1. Incidence of PPI prescriptions and time 
trends thereof (period 2012–2017)
2. Incidence of PIPPI and time trends 
thereof (period 2013–2017, PIPPI is 
defined as a result of the preceding year)
3. Association of patient characteristics 
with PIPPI (demographic characteristics, 
drugs with bleeding risk and number of 
chronic conditions) in comparison to PPI 
prescriptions
Assessment of proton-pump inhibitor 
prescribing
The insurance claims cover all pharmacy and 
physician invoices of prescription drugs. PPI were 
identified by Anatomical Therapeutic Chemical 
(ATC) Classification codes A02BC. Incidence of 
PPI prescriptions was defined by any such pre-
scription during any calendar year. All health care 
invoices submitted to Helsana for reimbursement 
during the study period were considered. 
Prescribed PPI doses of the various PPI products 
were converted into pantoprazole dose equivalents, 
thus referencing the most commonly prescribed 
PPI product in Switzerland. In an attempt to esti-
mate PPI prescribing in the context of clinical 
practice in Switzerland, doses of all the PPI agents 
on the market were labelled as either maintenance 
or therapeutic dose and then translated into pan-
toprazole dose equivalents of 20 mg and 40 mg, 
respectively. Detailed definitions of the various 
pantoprazole dose equivalents are listed under 
Supplemental Material (1).
Definition and assessment of potentially 
inappropriate proton-pump inhibitor prescribing
Based on a literature review covering 34 clinical 
practice guidelines in 2017, we extracted PPI 
dosage and treatment regimens on 57 different 
PPI indications.16 Thereof we derived a 365-day 
cumulative pantoprazole dose equivalent of 11.5 g 
as a cut-off for inappropriateness. This cut-off 
reflects an evidence-based maximal-dose sce-
nario, based on three hypothetical sequential 
phases: (1) an 8-week double-dose therapeutic 
treatment phase (2 × 40 mg of pantoprazole dose 
equivalents, i.e. for severe erosive esophagitis), 
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(2) a 4-week tapering to a therapeutic dose 
(1 × 40 mg), (3) a maintenance dose (1 × 20 mg) 
for the remainder of the year. The resulting 
cumulative yearly dose of 11.2 g of pantoprazole 
equivalents was rounded up to 11.5 g. PIPPI was 
then determined by screening every observed per-
son day for a preceding 365-day cumulative dose 
exceeding 11.5 g. To clarify we give a practical 
example: if 100 tablets pantoprazole 40 mg were 
dispensed 1 December 2016, this corresponded 
to 4000 mg added to the balance sheet of one 
patient. If the same patient repeated this process 
twice (i.e. adding another 8000 mg and therefore 
12,000 mg in total) before 30 November 2017, 
then this patient would be regarded as a dispenser 
of PIPPI for 2017 (on the day of the third dis-
pensing, i.e. when 11.5 g are exceeded).
Patient characteristics
Patient characteristics included gender, age and 
the number of chronic conditions according to 
ATC codes and pharmaceutical cost groups 
(PCG).17 Drugs which increase gastrointestinal 
bleeding risk and are therefore commonly associ-
ated with PPI co-prescriptions18 were assessed by 
translating the prescription of all such drugs into 
defined daily doses per patient per day, using cor-
responding ATC codes. These drugs were 
grouped as follows: Anticoagulant therapy includ-
ing vitamin K antagonists (ATC B01AA) and 
direct oral anticoagulants (ATC B01AF, B01AE), 
antiplatelet therapy including aspirin (ATC 
B01AC06) and other platelet inhibitors (ATC 
B01AC), systemic corticosteroids (ATC H02AB) 
and non-steroidal anti-inflammatory drugs 
(NSAIDs), including coxibs (ATC M01A, 
M01AH). The number of chronic conditions 
using PCGs was likewise applied on the basis of 
drug prescriptions, according to all concurrent 
ATC codes billed (including ATC code A02 for 
acid-related disorders) per calendar year per 
patient, and categorized as follows: 0 (reference 
group), 1–3 and ⩾4.
Statistics: analysis
We calculated the incidence of PPI prescriptions, 
being the first PPI prescription during a calendar 
year and the incidence of PIPPI, being patients 
crossing at least once the cumulative prescribed 
PPI cut-off dose of 11.5 g during any preceding 
365 days, counted per calendar year. Both meas-
ures used the total patients enrolled within the 
calendar year as the denominator. In addition, 
the incidence of PIPPI among the incidental PPI 
prescription group was calculated. Percentages 
and mean values were used to describe categori-
cal and nominal data, respectively. Descriptive 
statistics were used to provide characteristics of 
all patients with PPI prescriptions. These data 
were grouped into PPI prescriptions (i.e. non-
PIPPI) and PIPPI groups. Chi-Squared tests for 
trend in proportions were used to analyse changes 
in proportions of PPI prescriptions and PIPPI 
incidence. For bivariate comparisons between the 
PPI prescriptions and PIPPI groups, Kruskal–
Wallis, Fisher exact and Chi-Square tests were 
used accordingly. A two-sided p-value of 0.05 was 
considered statistically significant. To explore 
patient characteristics associated with PIPPI 
(dependent variable), we performed a multivari-
able logistic regression. Independent factors 
included in the regression model were age, gen-
der, prescription of drugs increasing bleeding risk 
(yes/no) and number of chronic conditions. The 
goodness-of-fit of the logistic regression model 
was assessed by calculating the area under the 
curve (AUC).
To investigate a potential dose–response relation-
ship between drugs increasing bleeding risk and 
PIPPI, we performed an additional analysis in 
which we included the absolute prescribed 
defined daily doses (DDDs)19 of any of the spe-
cific drug categories (dependent variables) into a 
regression model. For this purpose, we defined 
the corresponding time period in the group of PPI 
prescriptions as the 365 days’ period following the 
first prescription of a PPI (as opposed to the ret-
rospective 365 days in the PIPPI group). We pre-
sent results of regression analysis as odds ratios 
with 95% confidence intervals (95% CI). 
Statistical analyses were conducted with “R” ver-
sion 3.6.1 (2019-07-05).
Ethics
According to the Swiss national ethical and legal 
regulations, ethical approval from the local ethics 
committee was not needed for the study. As data 
were completely anonymized, no patient consent 
was necessary.
Results
The total amount of different persons accessible 
in our dataset throughout all years was 1,726,491. 
Therapeutic Advances in Gastroenterology 14
4 journals.sagepub.com/home/tag
After applying inclusion criteria, this number 
amounted to 1,337,722. The number of included 
persons is reported on a yearly basis in Table 1. 
The mean age during the observation period was 
51.2 years, 52.4% of persons were female.
Incidence of PPI prescriptions and PIPPI, rela-
tive proportions in the study population and the 
group with PPI prescriptions are reported in 
Table 1. The incidence of PPI prescriptions was 
23.0% in 2017, which reflects a steady rise since 
2012 (p = <0.001 for trend). The overall inci-
dence of PIPPI was 6.4% in 2017, corresponding 
to 27.8% of incident PPI prescriptions. Again, 
the positive trend for proportions since 2012 was 
statistically significant (p = <0.001 for trend).
All incident PPI prescriptions and PIPPI cases 
and corresponding patient characteristics are 
listed in Table 2. Patients with PIPPI were signifi-
cantly older and more often female (unadjusted 
analysis).
The majority of patients with PPI prescriptions or 
PIPPI were also prescribed drugs with increased 
bleeding risk at least once during the designated 
365-day periods, 63.3% and 86.0%, respectively. 
The highest incidence for a specific category of 
drugs with increased bleeding risk was observed 
for NSAIDs, with 50.9% and 62.0% of PPI pre-
scriptions and PIPPI patients exposed.
Overall, the majority of patients in both prescrip-
tion groups had at least one chronic condition: 
73.2% of patients in the PPI prescriptions as 
compared with 98% in the PIPPI group. In the 
PPI prescriptions group, 1–3 chronic conditions 
were most prevalent. In the PIPPI group, the pro-
portion of patients suffering from more than three 
chronic conditions reached 64%.
Results of the multivariable logistic regression of 
PIPPI and patient characteristics are presented in 
Table 3 and indicate that the model explains most 
of the variation of PIPPI (AUC 81.3%). In con-
trast to the bivariate comparison, female gender 
was independently associated with lower odds of 
PIPPI. All categories of concurrent drugs with 
bleeding risk and the number of chronic condi-
tions remained independently associated with 
higher odds of PIPPI.
The additional analysis assessing the association 
of PIPPI with DDDs of all drugs with bleeding 
risk showed a significant dose–response relation-
ship (Supplemental Material).
Discussion
In this large population-based study, one out of 
four adults was prescribed a PPI in 2017. Among 
these, one out of four was prescribed PIPPI based 
on cumulative doses not supported by clinical 
Table 1. Annual incidence of PPI and PIPPI prescribing. 
2012 2013 2014 2015 2016 2017
Persons accessible 
(n)
1,197,992 1,188,017 1,181,640 1,195,286 1,169,965 1,105,847
Persons included (n) 939,295 941,897 933,377 933,450 917,590 870,073
PPI prescription 
incidence (n) (%)*
185,093 (19.7%) 199,477 (21.2%) 207,908 (22.3%) 214,448 (23.0%) 215,219 (23.5%) 200,565 (23.1%)
PIPPI incidence  
(n) (%)*
25,639 (2.7%)† 45,055 (4.8%) 50,418 (5.4%) 54,575 (5.8%) 56,504 (6.2%) 55,685 (6.4%)
Incidence of 
PIPPI among PPI 
prescriptions (%)
13.9% 22.6% 24.3% 25.5% 26.3% 27.8%
PIPPI, potentially inappropriate proton-pump inhibitors; PPI, Proton-pump inhibitors.
*p = <0.001 for trend 2012–2017.
†Limited comparability of inception year inherent to definition of PIPPI. 
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practice guidelines. We found increasing annual 
incidence trends for both PPI prescriptions and 
PIPPI during the observed 6-year period. 
Multimorbidity and drugs with bleeding risk were 
strong independent determinants of PIPPI.
In our study, the proportion of patients with at 
least one PPI prescription per year was 19.7% in 
2012 and 23% in 2017. Corresponding rates 
from other health care systems varied between 
7.4% and 29.8%.13,14,20–22 The definition of inap-
propriateness and differences between popula-
tions (i.e. inclusion criteria) and health care 
systems, including varying degrees of over-the-
counter (OTC) dispensing, might explain some 
of this variance.
The annual incidence of PIPPI in our study rose 
from 4.8% in 2013 to 6.4% of all adults in 2017, 
corresponding to 27.8% of the population with an 
incidental PPI prescription. To our knowledge, 
there is no previous literature describing PIPPI 
with continuous, cumulative dose regimens on the 
patient level and based on clinical practice guide-
lines. Multiple studies have assessed the extent of 
PIPPI in various settings and with different defini-
tions of long-term use.12 Previous estimates have 
been highly variable and ranged from proportions 
of overuse from 11 to 84%.23 PIPPI was often 
ascertained either based on prescriptions exceed-
ing a certain amount of weeks,24,25 within specific 
age groups,25 specific situations such as drugs with 
bleeding risk,8 or as the absence of an appropriate 
clinical indication.14,26 A nationwide drug utiliza-
tion study in France reported 32.4% of new PPI 
users in the year 2015 without other drugs or diag-
noses to support an indication for PPI therapy,14 
yet only 4.1% of new PPI users received a contin-
uous PPI therapy lasting longer than 6 months. 
Another study assessed DDDs per patient but 
reported averages per calendar year, thereby leav-
ing uncertainty about the actual degree of PIPPI 
at the patient level.11 Nevertheless, some previous 
studies using different definitions of PIPPI, 
Table 2. Patient characteristics and comparison between PPI and PIPPI prescribing groups. 
Characteristics
 Total PPI PIPPI p-value for 
comparison
n 610,437 (100%) 367,159 (60.1%) 243,278 (39.9%)  
Age (SD) 58.5 (19.6) 52.2 (19.8) 68.1 (14.9) <0.001
Female gender (n) (%) 351,962 (57.7%) 209,852 (57.2%) 142,110 (58.4%) <0.001
Drugs with bleeding risk (n) (%)
 Anticoagulants 68,557 (11.2%) 23,839 (6.5%) 44,718 (18.4%) <0.001
 Antiplatelets 138,998 (22.8%) 46,971 (12.8%) 92,027 (37.8%) <0.001
 Corticosteroids 151,595 (24.8%) 63,498 (17.3%) 88,097 (36.2%) <0.001
 NSAIDs 337,758 (55.3%) 186,908 (50.9%) 150,850 (62.0%) <0.001
 Any (of the above) 441,746 (72.4%) 232,573 (63.3%) 209,173 (86.0%) <0.001
Number of chronic conditions (n) (%)
 0 100,474 (17.0%) 95,826 (26.8%) 4648 (2.0%) <0.001
 1–3 271,498 (45.9%) 191,706 (53.6%) 79,792 (34.1%) <0.001
 ⩾4 219,606 (37.1%) 69,810 (19.5%) 149,796 (64.0%) <0.001
NSAIDs, non-steroidal anti-inflammatory drugs; PIPPI, potentially inappropriate proton-pump inhibitors; PPI, proton-
pump inhibitors; SD, standard deviation.
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presented findings aligned with our results: a 
nationwide population-based study in Iceland 
found that 21% of incident high-dose PPI pre-
scriptions were still using high doses after 1 year.13
Our data show a significant increase of PPI pre-
scriptions and PIPPI over time. This phenome-
non was described previously.13,20,27 Whether this 
is merely a consequence of an increased preva-
lence of polypharmacy in an aging society,25 or 
pointing to challenges in the deprescribing pro-
cess, with patients reporting increased symptoms 
and lower satisfaction after withdrawal of PPI,28 
remains unclear based on our data.
Higher age was associated with PIPPI compared 
with PPI prescriptions, whereas female gender 
was not. Yet evidence with regard to gender as 
determinant of PIPPI is conflicting.24,29
Drugs with increased bleeding risk and especially 
NSAIDs were more common in the PIPPI group 
(62%), as compared with the PPI prescriptions 
group (50.9%). Similar proportions were reported 
elsewhere: NSAID co-use reached 48% in one 
study assessing long-term PPI prescriptions, and 
a recent population-based estimate attributed 
NSAID use to 53.3% of patients newly prescribed 
a PPI.21,14 Our finding remained stable after 
regression analysis, showing that all drugs with 
bleeding risk were independently associated with 
PIPPI. The effect of NSAIDs decreased with 
short-term NSAID use, presumably due to a large 
number of healthy patients within the sample. 
While these data underline the substantial contri-
bution of NSAIDs to PPI prescriptions, it remains 
unclear as to why exactly drugs with increased 
bleeding risk are associated to PIPPI (as opposed 
to PPI prescriptions). Interestingly, most guide-
lines commenting on prevention of NSAID-
associated ulcers and bleedings (as compared 
with other guidelines recommending PPIs) leave 
room for interpretation by omitting recommen-
dations on dose reduction in this specific con-
text.30–33 As physicians tend to overestimate the 
need for preventive PPI prescriptions,34 this might 
lead to prescriptions of higher doses more fre-
quently. Also, it is known that previously asymp-
tomatic patients can become symptomatic upon 
withdrawal of PPI drugs.35 Patients with preven-
tive PPI prescriptions might thus be at particular 
risk for the re-initiation of therapeutic doses, as 
Table 3. Adjusted association between PIPPI prescribing and patient characteristics.
Characteristics OR 95% CI p-value
Female gender 0.828 0.818–0.839 <0.001
Age (years) 1.027 1.027–1.027 <0.001
Drugs with bleeding risk
 Anticoagulants 1.376 1.350–1.403 <0.001
 Antiplatelets 1.466 1.443–1.488 <0.001
 Corticosteroids 1.557 1.536–1.580 <0.001
 NSAIDs 1.154 1.139–1.169 <0.001
Number of chronic conditions (reference = 0)
 Chronic conditions (=1–3) 5.112 4.953–5.275 <0.001
 Chronic conditions (⩾4) 16.632 16.094–17.188 <0.001
AUC 81.3%
AUC, area under the curve; 95% CI, 95% confidence intervals; NSAIDs, non-steroidal anti-inflammatory drugs; OR, odds 
ratio; PIPPI, potentially inappropriate proton-pump inhibitor.
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such prescriptions are often stopped abruptly in 
clinical practice, together with drugs increasing 
bleeding risk.
Furthermore, we found chronic conditions in 
98% of patients with PIPPI and in 73.1% of 
patients with PPI prescribing. In fact, an increas-
ing number of chronic conditions was the strong-
est predictor of PIPPI compared with PPI 
prescriptions in our logistic regression analysis. 
This finding has been described previously.21,25,36
Strengths of this study are its large and represent-
ative sample including roughly 1.2 million per-
sons, reflecting about 14% of the adult Swiss 
resident population.15 Furthermore, our method 
of defining PIPPI overcomes some of the variabil-
ity of past estimates. It does not depend on the 
documentation and identification of (often 
absent) disease- or drug-related reasons justifying 
PPI prescriptions. It also does not rely on meth-
ods based on treatment intervals or days covered, 
which might not capture the long-term recur-
rence of PPI prescriptions or the actual dosage 
prescribed. In addition, by using a continuous, 
‘rolling’ approach, our analysis is not restricted to 
calendar year boundaries and thereby can assess 
daily average doses over longer periods. The cho-
sen cut-off value for PIPPI (11.5 g) is based on a 
clinical worst-case scenario of maximally neces-
sary and sensible PPI intake, which only is sur-
passed in very seldom clinical situations.
This study has also limitations. We were not able 
to estimate OTC or hospital dispensing. However, 
available OTC formulations are low dose and 
small package size only, and patients are unlikely 
to use OTC PPI on a long-term basis, as costs are 
high and health insurance coverage is plenary. 
Furthermore, the effective ingestion of PPI of 
course remains unclear, as our data documents 
drug reimbursement only. Again, it is unlikely that 
a relevant amount of patients would regularly dis-
pense PPI on a long-term basis without actually 
ingesting them. Lastly, our sample does not con-
tain clinical data. We therefore cannot exclude 
potentially justified long-term, high-dose PPI 
treatments as occurs in very rare conditions. 
However, clinical recommendations for long-term 
prescriptions of therapeutic dose PPI are limited: 
Barrett-esophagus37 with a prevalence of <2% in 
the general adult population38 and Zollinger–
Ellison syndrome, which is exceedingly rare.39 It 
seems thus unlikely, that such disease-specific 
therapeutic dose PPI prescriptions would alter the 
general finding of this study, which affects a sub-
stantial share of the overall population.
Many studies observed side effects of PPI pre-
scriptions use without establishing causality,40 
but some trials did.41,42 In light of the widespread 
prescription of PPI, even the probability of rare or 
minor side effects should raise concern. 
Appropriate PPI prescriptions (and deprescrib-
ing) in the context of short-term preventive use 
(e.g. with NSAIDs) might be of special interest 
for further investigations. Co-occurrence is wide-
spread and specific recommendations on dose 
reductions are lacking. Our data portray a period 
when dose lowering and deprescribing of PPI 
should have been commonplace. The Choosing 
Wisely campaign in the US adopted this target in 
2012,10 which was widely received in Switzerland. 
Its Swiss offshoot Smarter Medicine43 absorbed the 
PPI lowering recommendation later, in 2015.
However, a systematic review reported PPI to be 
among the drugs most resistant to deprescrib-
ing.44 A call for more deprescribing45 might there-
fore not be enough. Some authors, as a 
consequence, believe that prescribing or paying 
restrictions (self-pay for high dose) should be put 
in place by authorities.21,45 We suggest that a 
standardized operationalization of PIPPI, as pre-
sented in this study, offers opportunities to meas-
ure PIPPI use more validly, to compare its 
occurrence across health service providers, set-
tings, and care models, and possibly to incentivize 
a more cautious use of PPI drugs, while increas-
ing transparency and awareness.
Conclusion
This study provides evidence that one of the most 
prescribed drug groups is commonly prescribed 
inappropriately in the general population and that 
this trend is increasing. Multimorbidity and drugs 
with bleeding risks were strong determinants of 
PIPPI. Addressing PPI prescriptions exceeding 
guideline recommendations could reduce polyp-
harmacy and improve patient safety.
Author contributions
All authors have been involved in the study con-
cept, design and interpretation of results. Andri 
Signorell collected and analysed the data, 
Leander Muheim drafted the article and all of 
the authors revised it critically. All authors 
Therapeutic Advances in Gastroenterology 14
8 journals.sagepub.com/home/tag
approved the final version of the article, includ-
ing the authorship list.
Conflict of interest statement
Helsana Group provided support in the form of 
salaries for authors AS and EB being employed by 
the Helsana Group. The funders had no role in 
the study design, data collection and analysis, 
decision to publish, or preparation of the manu-
script. AS and EB declare no conflict of interest. 
Helsana Group shall have no liability to any third 
party in respect of the contents of this article. All 
the other authors as well have no conflicts of 
interests or financial disclosures to declare.
Funding
The authors disclosed receipt of the following 
financial support for the research, authorship, 
and/or publication of this article: This study was 
supported by the Swiss Academy of Medical 
Sciences with an unrestricted grant.
Guarantor of the article
Leander Muheim
ORCID iD
Leander Muheim  https://orcid.org/0000-0002- 
7932-8134
Supplemental material
Supplemental material for this article is available 
online.
References
 1. Katz PO, Gerson LB and Vela MF. 
Guidelines for the diagnosis and management 
of gastroesophageal reflux disease. Am J 
Gastroenterol 2013; 108: 308–328; quiz 329.
 2. Schneider R, Reinau D, Schur N, et al. Helsana-
Arzneimittel. Report, Universität Basel, Ausgabe, 
2018, p.250.
 3. Poly TN, Islam MM, Yang H-C, et al. Proton 
pump inhibitors and risk of hip fracture: a meta-
analysis of observational studies. Osteoporos Int 
2019; 30: 103–114.
 4. Xie Y, Bowe B, Li T, et al. Risk of death among 
users of proton pump inhibitors: a longitudinal 
observational cohort study of United States 
veterans. BMJ Open 2017; 7: e015735.
 5. Makunts T, Cohen IV, Awdishu L, et al. Analysis 
of postmarketing safety data for proton-pump 
inhibitors reveals increased propensity for 
renal injury, electrolyte abnormalities, and 
nephrolithiasis. Sci Rep 2019; 9: 2282.
 6. Harrison SL, Kouladjian O’Donnell L, Milte 
R, et al. Costs of potentially inappropriate 
medication use in residential aged care facilities. 
BMC Geriatr 2018; 18: 9.
 7. Ladd AM, Panagopoulos G, Cohen J, et al. 
Potential costs of inappropriate use of proton 
pump inhibitors. Am J Med Sci 2014; 347: 
446–451.
 8. Chau SH, Sluiter RL, Hugtenburg JG, et al. 
Cost-utility and budget impact analysis for 
stopping the inappropriate use of proton pump 
inhibitors after cessation of NSAID or low-dose 
acetylsalicylic acid treatment. Drugs Aging 2020; 
37: 67–74.
 9. Kahrilas PJ, Shaheen NJ and Vaezi MF. 
American gastroenterological association medical 
position statement on the management of 
gastroesophageal reflux disease. Gastroenterology 
2008; 135: 1383–1391.e5.
 10. Treating GERD. American Gastroenterological 
Association. Choosing Wisely, http://www.
choosingwisely.org/clinician-lists/american-
gastroenterological-association-treating-gerd/ 
(accessed 12 March 2019).
 11. Haastrup P, Paulsen MS, Zwisler JE, et al. 
Rapidly increasing prescribing of proton pump 
inhibitors in primary care despite interventions: a 
nationwide observational study. Eur J Gen Pract 
2014; 20: 290–293.
 12. Raghunath AS, O’Morain C and Mcloughlin 
RC. Review article: the long-term use of proton-
pump inhibitors. Aliment Pharmacol Ther 2005; 
22(Suppl. 1): 55–63.
 13. Hálfdánarson ÓÖ, Pottegård A, Björnsson ES, 
et al. Proton-pump inhibitors among adults: a 
nationwide drug-utilization study. Therap Adv 
Gastroenterol 2018; 11: 1756284818777943.
 14. Lassalle M, Le Tri T, Bardou M, et al. Use of 
proton pump inhibitors in adults in France: a 
nationwide drug utilization study. Eur J Clin 
Pharmacol 2020; 76: 449–457.
 15. Tabelle. Bilanz der ständigen Wohnbevölkerung, 
1861-2018. Bundesamt für Statistik, https://
www.bfs.admin.ch/bfs/de/home/statistiken/
bevoelkerung/stand-entwicklung/bevoelkerung.
assetdetail.13707405.html (2019, accessed 21 
June 2020).
 16. Ursprung P. Protonenpumpenhemmer in klinischen 
guidelines. Master Thesis, Medical Faculty 
University of Zurich, Switzerland, 2020.
L Muheim, A Signorell et al.
journals.sagepub.com/home/tag 9
 17. Huber CA, Szucs TD, Rapold R, et al. 
Identifying patients with chronic conditions 
using pharmacy data in Switzerland: an updated 
mapping approach to the classification of 
medications. BMC Public Health 2013; 13: 
1030.
 18. Lin KJ, Hernández-Díaz S and García 
Rodríguez LA. Acid suppressants reduce risk 
of gastrointestinal bleeding in patients on 
antithrombotic or anti-inflammatory therapy. 
Gastroenterology 2011; 141: 71–79.
 19. WHO Collaborating Centre for Drug Statistics 
Methodology. ATC/DDD index, https://www.
whocc.no/atc_ddd_index/ (accessed 21 August 
2018).
 20. Othman F, Card TR and Crooks CJ. Proton 
pump inhibitor prescribing patterns in the UK: a 
primary care database study. Pharmacoepidemiol 
Drug Saf 2016; 25: 1079–1087.
 21. Daniels B, Pearson S-A, Buckley NA, et al. 
Long-term use of proton-pump inhibitors: 
whole-of-population patterns in Australia 
2013-2016. Therap Adv Gastroenterol 2020; 13: 
1756284820913743.
 22. Pottegård A, Broe A, Hallas J, et al. Use of 
proton-pump inhibitors among adults: a Danish 
nationwide drug utilization study. Therap Adv 
Gastroenterol 2016; 9: 671–678.
 23. Naunton M, Peterson GM, Deeks LS, et al. We 
have had a gutful: the need for deprescribing 
proton pump inhibitors. J Clin Pharm Ther 2018; 
43: 65–72.
 24. Moriarty F, Bennett K, Cahir C, et al. 
Characterizing potentially inappropriate 
prescribing of proton pump inhibitors in older 
people in primary care in Ireland from 1997 to 
2012. J Am Geriatr Soc 2016; 64: e291–e296.
 25. Cahir C, Fahey T, Teeling M, et al. Potentially 
inappropriate prescribing and cost outcomes for 
older people: a national population study.  
Br J Clin Pharmacol 2010; 69: 543–552.
 26. Levy-Neumand O, Carniaux F, Bonaz B, et al. 
Proton pump inhibitors in general medicine. 
Comparison of routine practices with marketing 
authorization indications. Gastroenterol Clin Biol 
2007; 31: 78–83.
 27. Haastrup PF, Paulsen MS, Christensen RD, et al. 
Medical and non-medical predictors of initiating 
long-term use of proton pump inhibitors: a 
nationwide cohort study of first-time users during 
a 10-year period. Aliment Pharmacol Ther 2016; 
44: 78–87.
 28. Boghossian TA, Rashid FJ, Thompson W, et al. 
Deprescribing versus continuation of chronic 
proton pump inhibitor use in adults. Cochrane 
Database Syst Rev 2017; 3: CD011969.
 29. Wallerstedt SM, Fastbom J, Linke J, et al. 
Long-term use of proton pump inhibitors and 
prevalence of disease- and drug-related reasons 
for gastroprotection-a cross-sectional population-
based study. Pharmacoepidemiol Drug Saf 2017; 
26: 9–16.
 30. Laine L and Jensen DM. Management of patients 
with ulcer bleeding. Am J Gastroenterol 2012; 107: 
345–360.
 31. Malfertheiner P, Megraud F, O’Morain CA, et al. 
Management of Helicobacter pylori infection—
the Maastricht IV/ Florence Consensus Report. 
Gut 2012; 61: 646–664.
 32. Satoh K, Yoshino J, Akamatsu T, et al. Evidence-
based clinical practice guidelines for peptic ulcer 
disease 2015. J Gastroenterol 2016; 51: 177–194.
 33. Fischbach W, Malfertheiner P, Jansen PL, 
et al. S2k-leitlinie helicobacter pylori und 
gastroduodenale Ulkuskrankheit. Z Gastroenterol 
2016; 54: 327–363.
 34. Murthy SK, Kauldher S and Targownik 
LE. Physicians’ approaches to the use of 
gastroprotective strategies in low-risk non-
steroidal anti-inflammatory drug users. Aliment 
Pharmacol Ther 2006; 23: 1365–1372.
 35. Reimer C, Søndergaard B, Hilsted L, et al. 
Proton-pump inhibitor therapy induces acid-
related symptoms in healthy volunteers after 
withdrawal of therapy. Gastroenterology 2009; 
137: 80–87, 87.e1.
 36. Voukelatou P, Vrettos I, Emmanouilidou G, 
et al. Predictors of inappropriate proton pump 
inhibitors use in elderly patients. Curr Gerontol 
Geriatr Res 2019; 2019: 7591045.
 37. Jankowski JAZ, de Caestecker J, Love SB, et al. 
Esomeprazole and aspirin in Barrett’s oesophagus 
(AspECT): a randomised factorial trial. Lancet 
2018; 392: 400–408.
 38. Ronkainen J, Aro P, Storskrubb T, et al. 
Prevalence of Barrett’s esophagus in the general 
population: an endoscopic study. Gastroenterology 
2005; 129: 1825–1831.
 39. Öberg K and Eriksson B. Endocrine tumours 
of the pancreas. Best Pract Res Clin Gastroenterol 
2005; 19: 753–781.
 40. Yadlapati R and Kahrilas PJ. When is proton 
pump inhibitor use appropriate? BMC Med 2017; 
15: 36.
Therapeutic Advances in Gastroenterology 14
10 journals.sagepub.com/home/tag
 41. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety 
of proton pump inhibitors based on a large, 
multi-year, randomized trial of patients receiving 
rivaroxaban or aspirin. Gastroenterology 2019; 
157: 682–691.e2.
 42. Writing Committee for the American Lung 
Association Asthma Clinical Research Centers, 
Holbrook JT, Wise RA, et al. Lansoprazole for 
children with poorly controlled asthma: a randomized 
controlled trial. JAMA 2012; 307: 373–381.
 43. smarter medicine - Choosing Wisely Switzerland. 
Top-5-Listen – Ambulante Allgemeine Innere 
Medizin, https://www.smartermedicine.ch/ 
(accessed 20 January 2021).
 44. Dills H, Shah K, Messinger-Rapport B,  
et al. Deprescribing medications for chronic 
diseases management in primary care settings: a 
systematic review of randomized controlled trials. 
J Am Med Dir Assoc 2018; 19: 923–935.e2.
 45. Henderson J, Bouck Z, Holleman R, et al. 
Comparison of payment changes and choosing 
wisely recommendations for use of low-value 
laboratory tests in the United States and Canada. 
JAMA Intern Med 2020; 180: 524–531.
Visit SAGE journals online 
journals.sagepub.com/
home/tag
SAGE journals
